Track market-moving stories before they get noisy

Chainlink Data Feeds went live on Tempo on Sept. 3, providing the payments-focused blockchain with onchain market data for stablecoin and financial applications.

Summary

Chainlink Data Feeds are now live on Tempo, supplying market prices directly to financial applications. Developers can use supported feeds for collateral valuation, exchange-rate comparisons, treasury controls and reconciliation workflows. Independent Chainlink node operators aggregate multiple data sources before publishing reports that contracts can verify. Tempo provides execution and settlement, while applications determine how incoming market information controls transactions automatically. LINK traded near $11.84, rising about 5.6%, without confirmed evidence connecting gains to integration news. The integration allows businesses, institutions and developers to access supported price feeds without building independent oracle infrastructure. Applications can use the data for collateral valuation, foreign exchange comparisons, treasury management and automated risk controls.

Chainlink Data Feeds support financial applications Blockchains cannot independently obtain market information from external exchanges and financial data providers. Oracle networks deliver that information to smart contracts, allowing applications to respond to price changes and other offchain events.

Chainlink Data Feeds are now live on Tempo.

Businesses and developers can use @chainlink’s industry-standard infrastructure to value collateral, compare FX rates, and automate risk controls while eliminating the need to build and maintain custom oracle infrastructure. pic.twitter.com/LVChhzeMC1

— Tempo (@tempo) September 3, 2026 Chainlink aggregates observations from multiple data providers. Independent node operators collect the information before publishing reports that smart contracts can verify on Tempo.

Tempo provides the execution and settlement layer, while developers decide how applications use the information. A lending application, for example, can reference a feed when calculating collateral values, borrowing limits and the health of open positions.

Developers can review the available feeds and contract addresses through Chainlink’s documentation. The companies did not state how many applications currently use the feeds.

Tempo targets stablecoin payment infrastructure Tempo is a layer-1 blockchain designed for stablecoin payments and financial settlement. Stripe and crypto investment company Paradigm incubated the project before its mainnet launch in March 2026.

The network is intended to support uses such as business payments, payroll, remittances and machine-generated transactions. As previously reported, Tempo launched its mainnet and machine-payment protocol to process stablecoin transfers for businesses and artificial intelligence agents.

Market data expands the functions applications can build around those payments. A business could compare a foreign exchange quote with an external reference rate before approving a conversion. Treasury software could also rebalance positions when an asset moves outside a predefined range.

Tempo said applications could use stablecoin balances as collateral for working capital and other liquidity products. These remain potential applications rather than evidence that specific products have launched.

“Financial applications built around those payments need dependable market data to value collateral, compare exchange rates, and manage risk,” Tempo’s Eric Kang said.

Chainlink data can automate collateral controls The feeds can allow lending applications to monitor collateral without relying on a single exchange or data provider. Developers can program borrowing limits, liquidation thresholds and collateral top-up requirements around the incoming reference prices.

Tempo applications can also use the feeds to value different assets in one reporting currency. This could support accounting, position reconciliation and exposure monitoring across stablecoins or tokenized assets.

The integration follows Tempo’s expansion beyond basic payments. In May, the network integrated Morpho’s lending infrastructure, adding decentralized credit markets to the chain. The rollout brought fixed and variable lending tools to Tempo while preserving its payments-focused design.

Chainlink has also extended its data services across other tokenized markets. In August, it introduced price feeds for four Coinbase-issued tokenized U.S. stocks on Base, allowing supported applications to assess tokenized equities for lending and collateral.

Meanwhile, Chainlink Data Feeds provide reference prices rather than executing transactions themselves. Tempo applications remain responsible for selecting feeds, setting risk limits and determining how they respond when prices move. Developers must also account for update frequency, deviation thresholds and periods when market data becomes unavailable.

LINK rises as Chainlink integrations expand Chainlink traded near $11.84 when checked, up approximately 5.6% over the previous session. It reached an intraday high near $12 after trading as low as $11.13.

Chainlink (LINK) price chart, source: crypto.news No verified evidence directly connected the price increase to the Tempo announcement. LINK traded within a broader crypto market advance, making attribution to one integration unreliable.

Chainlink has secured several institutional and public-sector integrations in recent months. Wyoming recently adopted its Proof of Reserve system to publish near-real-time backing data for the state-issued FRNT stable token. The system adds onchain reserve verification to Wyoming’s daily attestations.

The next measure of the Tempo integration will be developer adoption. Tempo has not announced a deadline for additional feeds or named applications preparing to launch with the data. Supported contracts are already available for developers to integrate.

Casey’s General Stores, Inc. (NASDAQ:CASY) will release its first earnings report after the closing bell on Tuesday, Sept. 8.

Analysts expect the Ankeny, Iowa-based company to report quarterly earnings of $6.81 per share, up from $5.77 per share in the year-ago period. The consensus estimate for Casey’s quarterly revenue is $5.56 billion. It reported $4.57 billion last year, according to Benzinga Pro.

On June. 9, Caseys General Stores reported better-than-expected fourth-quarter financial results.

Casey’s shares rose 0.6% to close at $758.42 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

UBS analyst Mark Carden maintained a Neutral rating and cut the price target from $945 to $925 on Aug. 27, 2026. This analyst has an accuracy rate of 68%. BMO Capital analyst Kelly Bania upgraded the stock from Market Perform to Outperform rating with a price target of $950 on June 29, 2026. This analyst has an accuracy rate of 67%. BNP Paribas analyst Steve McManus maintained an Outperform rating and raised the price target from $995 to $1,030 on June 25, 2026. This analyst has an accuracy rate of 71%. Goldman Sachs analyst Bonnie Herzog maintained a Neutral rating and boosted the price target from $695 to $795 on June 25, 2026. This analyst has an accuracy rate of 64%. RBC Capital analyst Irene Nattel maintained a Sector Perform rating and increased the price target from $794 to $850 on June 25, 2026. This analyst has an accuracy rate of 56%. Trending

Considering buying CASY stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Pons said Uniswap Labs purchased its token "for long-term alignment" four weeks after Uniswap Labs put a rival launchpad on Robinhood Chain. Neither company disclosed the size of the purchase, the price paid, or the wallet holding it.

Uniswap Labs has bought PONS, the token of the memecoin launchpad that takes most of the launchpad fees paid on Robinhood Chain, the launchpad said on Thursday.

The purchase gives Uniswap Labs a stake in the application feeding the chain that now carries most of Uniswap V4's trading. Pons V2 routes tokens that graduate off its bonding curve into Uniswap V4 pools, and Robinhood Chain accounts for 56.3% of Uniswap V4 volume across all networks.

Pons announced the purchase at 5:24 p.m. ET, writing that Uniswap Labs "has purchased $PONS for long-term alignment" and calling it a deepening of its partnership with Uniswap. The post drew more than 200,000 views in under two hours. The Uniswap account quote-posted it with the emoji.

Acquisition Or AllocationNeither party disclosed how many tokens changed hands, what was paid, when the buying happened, or which address holds the position. Pons did not say whether Uniswap Labs bought on the open market or received an allocation, a distinction its followers raised repeatedly in the replies. Uniswap Labs has published no statement of its own.

Pons launched on July 13 and shipped its V2 contracts on Aug. 3. Its token trades on Robinhood Chain at contract 0x39dbed3a2bd333467115de45665cc57f813c4571, according to CoinGecko.

Rivals On The Same ChainUniswap Labs launched Pools.trade on Robinhood Chain on Aug. 5, charging 0.25% per trade and nothing to launch a token. It out-launched Pons on its first day. By Aug. 31, Pools.trade was collecting $38,553 a day in fees against $4.89 million for Pons V2.

Pons has since pulled ahead of every launchpad in crypto. It earned $5.95 million in fees over the past 24 hours, $28.83 million over seven days and $40.84 million over 30 days, DefiLlama data shows, keeping $1.11 million of the daily total as protocol revenue. It has out-earned Solana's pump.fun on daily fees every day since Aug. 29, after leading for six days in late July and then falling behind for a month.

Where Uniswap V4 TradesUniswap V4 handled $1.6 billion in volume over 24 hours across all chains. Robinhood Chain accounted for $901.5 million of that, against $465.5 million on Ethereum, $93.9 million on BNB Chain and $52.5 million on Base, according to DefiLlama. Uniswap's deployment on Robinhood Chain holds $207 million in total value locked and took $7.72 million in fees over the past day.

The chain itself settled $1.35 billion in DEX volume over 24 hours, with total value locked at $818.6 million, up 9.1% on the day, and stablecoins at $868.5 million. It earned $4.45 million in gas fees and $4.01 million in revenue, net of Ethereum settlement costs and the 10% share owed to Arbitrum.

PONS At A RecordPONS traded at $0.5013, up 17.5% over 24 hours, for a market capitalization of $357.1 million and a rank of 118, according to CoinGecko. The token set an all-time high of $0.5242 earlier Thursday, a day after Binance added it to Binance Alpha 1.0 alongside FLORK, and traded as low as $0.3476 in the same window. Turnover was $135.2 million.

UNI traded at $6.28, up 7.9% over 24 hours and 36.1% over seven days, for a market capitalization of $3.92 billion.

Burning Its Own SupplyPons directs about 80% of protocol fees toward buying PONS, according to the protocol and DefiLlama's accounting of its revenue. Pons said on Thursday that 29.34% of the total supply has been burned to date. Circulating supply stands at 712.1 million against a 1 billion maximum, CoinGecko data shows.

Stock Tokens And MemesRobinhood built the chain to trade tokenized equities and launched mainnet on July 1. Memecoin issuance arrived in week one, launch platforms began pairing memecoins with tokenized equities, and the network passed Ethereum on daily application revenue on Aug. 29. Pons listed a new set of stock-token pairs on Thursday, including UPS, SNAP, LULU, PFE and JNJ.

Onchain figures via DefiLlama and prices via CoinGecko as of 23:10 UTC on Sept. 3.

,

Following a competitive evaluation process, Studsvik has selected GE Vernova Hitachi Nuclear Energy and Samsung C&T as its strategic partners for the first project to build new nuclear power, either at its existing licensed nuclear site in or at the Målma site in Valdemarsvik. Together with GE Vernova Financial Services and DS Investment Partners, the companies will advance an initial four-unit BWRX-300 project in Sweden, totalling 1.2 GW of new nuclear generating capacity, with the first unit expected in operation in the mid-2030s. /PRNewswire/ -- Studsvik AB (publ), GE Vernova Hitachi Nuclear Energy, GE Vernova Financial Services, DS Investment Partners and Samsung C&T today announced an agreement to advance the ReFirm nuclear programme at Studsvik's sites in Sweden. The agreement is exclusive for a fixed period, which the parties may extend.

ReFirm is a multi-site small modular reactor (SMR) and new nuclear development program that became part of the Studsvik Group through the acquisition of Kärnfull Next (KNXT) earlier this year. KNXT has worked with GE Vernova Hitachi on BWRX-300 deployment in Sweden since 2022 and entered a strategic teaming agreement with Samsung C&T in December 2024. Today's announcement covers sites at Nyköping and Valdemarsvik and provides for development to commence with a four-unit BWRX-300 project of approximately 1,200 MWe in total at one of them.

At Nyköping, Studsvik operates an existing licensed nuclear facility. At Valdemarsvik, an application was submitted in March 2026, the first made under Sweden's new legislation requiring government approval for nuclear facilities. Which site hosts the first project will be decided during the development work.

The phased, multi-unit structure is intended to support standardisation across the programme and creates opportunities to capture lessons learned from early deployment and apply them to subsequent units, helping improve cost, schedule and productivity outcomes.

It will also help maximise Swedish industrial participation throughout engineering, procurement, construction, and long-term operations. This reflects the broader objective of building a supply chain that can support not only the first project, but also follow-on units and wider deployment opportunities in Sweden and Europe.

Studsvik has worked in nuclear technology for more than 75 years, and that capability is what a new plant needs to get through design, qualification and commissioning. Beyond any equity participation, a domestic new-build programme of this scale is expected to create long-term opportunities for Studsvik's services over the operating life of the plants.

The agreement marks the next phase of development and does not constitute a final investment decision or authorisation to construct. The parties will begin joint development work immediately, including commercial, technical, regulatory and financing activities during the exclusivity period.

Studsvik leads permitting, the environmental impact assessment, site rights, community engagement and the dialogue with the Swedish state. GE Vernova Hitachi leads reactor design, licensing support and cost estimation and acts as design authority, and, together with Samsung C&T, acts as the execution team, giving the project single-point responsibility for design and construction delivery. During the exclusivity period, DS Investment Partners, a South Korean investment firm, will lead the investment and GE Vernova Financial Services participates in an advisory and financial structuring capacity in support of the consortium.

A joint project company will be established to support development, financing, construction, ownership and operation of the plants, with details to be finalised in definitive agreements.

Sweden is expanding nuclear capacity under legislation in force since 2026 that permits reactors at sites beyond the three existing plants and requires government approval for each, supported by a state financing framework of loans and two-way contracts for difference.

"Sweden's electricity supply is a long-term play: existing nuclear capacity is ageing, and demand for baseload power is growing. To meet that, we have looked for long-term partners and for the conditions that let projects like this succeed. In GE Vernova Hitachi and Samsung C&T we have found them. We intend to build the first project either on an existing nuclear site or on greenfield. One reactor is a project. Four is the start of an industry."

- Karl Thedéen, President and Chief Executive Officer, Studsvik

"Today's announcement is about helping Sweden turn its energy ambitions into reality in a timeframe that matters for its communities and industries. The country has a strong foundation of nuclear expertise and operational excellence, and the BWRX-300 combines proven boiling water reactor technology with the lessons being learned every day at the Darlington New Nuclear Project in Canada. Together with a growing global pipeline of projects across North America and Europe, this experience gives Sweden access to a technology that is moving from first-of-a-kind deployment toward fleet-scale execution."

- Jason Cooper, Chief Executive Officer, GE Vernova Hitachi Nuclear Energy

"Samsung C&T is honoured to partner with Studsvik, GE Vernova Hitachi and the other members of the development team to support Sweden's next generation of nuclear energy. By combining proven technology, world-class EPC execution, operational excellence and financing capability, we are establishing a strong foundation for the successful development of the ReFirm programme. We are equally committed to strengthening Sweden's industrial capability, expanding local supply chains and building a long-term strategic partnership that creates lasting value for Studsvik and Sweden."

- Oh Se-chul, President and Chief Executive Officer, Engineering & Construction Group, Samsung C&T

Today's announcement is not expected to have any material financial impact on the Studsvik Group's earnings for 2026.

About Studsvik

Studsvik is an independent nuclear technology company active across the full nuclear lifecycle, from new build development to existing fleet services, operations support and decommissioning. It is a leading supplier of vendor-independent reactor analysis software, and its hot cell laboratories in Nyköping test fuel and materials for fission and fusion applications worldwide. Studsvik also provides radiation protection services and technology for treating radioactive waste, and handles and packages radioisotopes for healthcare and industry. ReFirm is Studsvik's platform for new nuclear development in Sweden. Founded in 1947 as the centre of Sweden's national nuclear programme, Studsvik today serves operators, fuel vendors, technology developers and regulators in more than 20 countries, has approximately 540 employees in six countries, and is listed on Nasdaq Stockholm (SVIK).

About Samsung C&T

Samsung C&T's Engineering & Construction Group has more than 40 years of engineering and construction experience operating throughout the world. The group spans commercial and residential buildings, civil infrastructure and plant construction. Its landmark projects include Burj Khalifa, the world's tallest building, the ongoing Riyadh Metro Project in Saudi Arabia, the Qurayyah 4,000MW CCPP Project, and the ongoing Qatar 2,000MW Solar Power Project. In the nuclear energy sector, the company has successfully delivered 12GW across 10 units, including the 5.6GW Barakah Nuclear Power Plant in the UAE. It has recently undertaken the Nuclear Power Plant refurbishment project and Front-End Engineering Design (FEED) for Small Modular Reactors (SMRs), demonstrating its global competitiveness in large-scale reactor and SMR technologies, and solidifying its expertise across all areas of the nuclear industry.

About GE Vernova Hitachi

GE Vernova's Nuclear energy business, through its global alliance with Hitachi Ltd., is a world-leading provider of nuclear services and advanced nuclear reactor designs. Technologies include boiling water reactors and small modular reactors, such as the BWRX-300, which is one of the simplest, yet most innovative boiling water reactor designs. GE Vernova's Nuclear fuel business, Global Nuclear Fuel (GNF), is a world-leading supplier of boiling water reactor fuel and fuel-related engineering services. GNF is a GE Vernova-led joint venture with Hitachi, Ltd. and operates primarily through Global Nuclear Fuel-Americas, LLC in Wilmington, N.C., and Global Nuclear Fuel-Japan Co., Ltd. in Kurihama, Japan. HITACHI is a trademark of Hitachi, Ltd. used under trademark license. GE is a trademark of General Electric Company used under trademark license.

About DS Investment Partners

DS Investment Partners (DSIP) is a Seoul-based investment firm focused on energy, technology, healthcare and strategic infrastructure sectors. Working alongside technology providers, industrial partners and institutional investors across Asia, the Middle East, Europe and North America, DSIP seeks to support investments that enhance security, reliability and long-term sustainability while creating value for stakeholders.

About GE Vernova

GE Vernova Inc. (NYSE: GEV) is a purpose-built global energy company that includes Power, Wind, and Electrification segments and is supported by its accelerators. Building on over 130 years of experience tackling the world's challenges, GE Vernova is uniquely positioned to help lead the energy transition by continuing to electrify the world while simultaneously working to decarbonize it. GE Vernova helps customers power economies and deliver electricity that is vital to health, safety, security, and improved quality of life. GE Vernova is headquartered in Cambridge, Massachusetts, U.S., with approximately 75,000 employees across 100+ countries around the world. Supported by the Company's purpose, The Energy to Change the World, GE Vernova technology helps deliver a more affordable, reliable, sustainable, and secure energy future.

GE Vernova's Financial Services business provides customers with a suite of financing solutions for projects that aim to accelerate a new era of energy. It has deployed sizeable capital into energy projects globally through development financing, direct equity investments, and capital raising from private and public financial institutions.

Disclosure

This information is information that Studsvik AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation and Sweden's Securities Markets Act. The information was released for public disclosure, through the agency of the contact person above, on 3 September 2026 at 07:30 CEST.

Forward-Looking Statements

Studsvik: This press release contains statements regarding future circumstances, including the timing of investment decisions, capacity, permitting processes and financing. Such statements are subject to uncertainty and actual outcomes may differ materially from those expressed or implied.

GE Vernova: This document contains forward-looking statements, that is, statements related to future events that by their nature address matters that are, to different degrees, uncertain. These forward-looking statements often address GE Vernova's expected future business and financial performance and financial condition, and the expected performance of its products, the impact of its services and the results they may generate or produce, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "estimate," "forecast," "target," "preliminary," or "range." Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about planned and potential transactions, investments or projects and their expected results and the impacts of macroeconomic and market conditions and volatility on the Company's business operations, financial results and financial position and on the global supply chain and world economy.

For more information, please contact

Karl Thedéen, President and Chief Executive Officer, Studsvik AB (publ), +46 155 22 10 00

Media enquiries: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/studsvik-ab/r/studsvik--ge-vernova-hitachi-and-samsung-c-t-commit-to-advancing-1-2-gw-nuclear-power-project-in-swe,c4391372

The following files are available for download:

https://mb.cision.com/Public/4019/4391372/8a778a2d5b07e45b.pdf

Press Release Studsvik GE Vernova Hitachi and Samsung C T commit to advancing 1 2 GW nuclear power project in Sweden September 2026

https://news.cision.com/studsvik-ab/i/jasoncooper-sechuloh-karlthedeen-seungsukang-patrickleahy,c3561730

JasonCooper SeChulOh KarlThedeen SeungSuKang PatrickLeahy

https://news.cision.com/studsvik-ab/i/gvh-bwrx-300,c3561724

GVH BWRX-300

https://news.cision.com/studsvik-ab/i/smr-campus-9units-illustration,c3561731

SMR Campus 9units Illustration

https://news.cision.com/studsvik-ab/i/smr-campus-illustration,c3561733

SMR Campus Illustration

https://news.cision.com/studsvik-ab/i/karl-thedeen-ceo-studsvik,c3561732

Karl Thedeen CEO Studsvik

https://news.cision.com/studsvik-ab/i/christian-sjolander-head-of-new-build-projects-studsvik,c3561725

Christian Sjölander Head Of New Build Projects Studsvik

SOURCE Studsvik AB

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™ (zilganersen) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is the first and only disease modifying treatment for AxD, an ultra-rare, progressive and often fatal neurological disorder that can affect motor, cognitive, autonomic and gastrointestinal function. Until now, treatment of AxD has primarily been limited to managing symptoms. ZANVASTRO is an RNA-targeted medicine designed to address the underlying disease mechanism of AxD by reducing the production of glial fibrillary acidic protein (GFAP). ZANVASTRO 50 mg is administered quarterly as an intrathecal (IT) injection.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903826844/en/

ZANVASTRO (zilganersen) logo

“Today’s approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no treatment options,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “This transformative approval also marks our first independent launch from our industry-leading neurology pipeline and underscores the power of our RNA-targeted technology to address serious neurological diseases without adequate treatment options. We are proud to bring this important new treatment to this incredible community and are deeply grateful to the clinical trial participants and their families, regulators, investigators and advocates who helped make this advancement possible.”

AxD affects approximately 1 in 1 to 3 million people worldwide. Initial signs of AxD can present from infancy through adulthood and may vary depending on age of onset. As AxD progresses, symptoms may include progressive motor and cognitive dysfunction, a loss of independence and the inability to control muscles for swallowing, airway protection and purposeful movements. AxD is caused by changes in the GFAP gene that lead to the overproduction and toxic accumulation of GFAP in astrocytes. Over time, dysfunction in astrocytes can damage neurons and myelin, which can lead to symptoms commonly associated with AxD.

“For decades, care for people living with Alexander disease has focused primarily on managing symptoms, without an option to modify the underlying cause of disease,” said Amy Waldman, M.D., M.S.C.E., pediatric neurologist and lead investigator for the ZANVASTRO study at Children’s Hospital of Philadelphia. “The approval of ZANVASTRO for the treatment of Alexander disease represents a significant advancement in care and opens new possibilities for patients and their families. For the first time, we can move beyond managing individual manifestations of the disease to addressing its underlying biology, with the potential to meaningfully improve outcomes for this community.”

“As a mom to a young boy living with Alexander disease and an advocate for this community, I have seen firsthand the profound impact this disease has on individuals and their families. Today’s approval represents a fundamental shift, changing the conversation from ‘How do we manage this disease’ to ‘How can we treat it,’” said Emily Petty, president, End Alexander Disease. “For far too long, receiving a diagnosis of Alexander disease was accompanied by uncertainty and the difficult reality that there were no available treatments. Today, that begins to change. ZANVASTRO marks a defining moment and brings a new sense of possibility to our community.”

The FDA approval was based on positive results from the pivotal study of ZANVASTRO in people living with AxD. The pivotal study met its primary endpoint in individuals ≥ 5 years of age, with ZANVASTRO 50 mg demonstrating statistically significant and clinically meaningful stabilization of gait speed as assessed by the 10-Meter Walk Test (10MWT), a commonly used measure of gross motor function in neurologic disease, compared to control at Week 61 (least square mean difference 33.3%, p=0.041). ZANVASTRO also demonstrated improvement in gross motor function in patients 2 to 4 years of age as assessed by the Gross Motor Function Measure-88 (GMFM-88), a well-established motor endpoint, compared to control at Week 61. Secondary and exploratory endpoint results from patient/caregiver- and clinician-reported outcome assessments consistently favored ZANVASTRO.

ZANVASTRO demonstrated a favorable safety and tolerability profile, with most adverse events (AEs) being mild or moderate in severity. Serious treatment-emergent adverse events (TEAEs) occurred less frequently in the ZANVASTRO group compared to control.

Ionis is committed to helping people access the medicines they are prescribed and will offer a full suite of services for people prescribed ZANVASTRO through Ionis Every Step™. As part of Ionis Every Step, patients will have access to a wide range of support and resources including disease state and product education for patients and caregivers, access to a dedicated Patient Education Manager, assistance with the insurance approval process, information on affordability programs and other ongoing services and resources throughout the treatment journey. Visit ZANVASTRO.com for more information.

With the approval of ZANVASTRO, the FDA granted Ionis a Rare Pediatric Disease Priority Review Voucher (PRV), a program designed to incentivize the development of therapies for serious and life-threatening diseases by providing a mechanism to potentially accelerate regulatory review timelines for subsequent applications.

ZANVASTRO will be available in the U.S. in the coming weeks.

In June 2026, Ionis entered into a license agreement with Recordati, a global pharmaceutical company headquartered in Italy, focused on specialty and rare diseases, under which Recordati obtained exclusive rights to develop and commercialize zilganersen in all countries outside the U.S. Ionis is working closely with Recordati on preparing regulatory submissions in Europe and Japan, which are expected in 2027.

Webcast

Ionis will hold a webcast on Friday, Sept. 4 at 10:00 a.m. ET to discuss the FDA approval. Interested parties may access the webcast here. A webcast replay will be available for a limited time.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Aseptic Meningitis

If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.

Adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) were reported in patients treated with ZANVASTRO during the double-blind and open-label periods of Study 1. One patient experienced a serious adverse reaction of aseptic meningitis during the double-blind treatment period of Study 1, which reoccurred in the open-label extension period and required dose interruption and pretreatment with intravenous dexamethasone prior to subsequent administration of ZANVASTRO. Despite corticosteroid premedication, CSF white blood cell (WBC) and protein increased with continued exposure, but the patient remained asymptomatic and did not require discontinuation from treatment. In addition, nonserious adverse drug reactions of CSF WBC increases have also been reported with ZANVASTRO.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥25% patients treated with ZANVASTRO and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.

Patients Less Than 2 Years of Age
The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older.

Please see full Prescribing Information for ZANVASTRO.

About the ZANVASTRO Study

The global, multicenter, randomized, double-blind, controlled, multiple-ascending dose (MAD) Phase 1-3 study (NCT04849741) enrolled 54 participants with Alexander disease (AxD) between the ages of 1.5 and 53 years across 13 sites in eight countries. Most participants in the study were children, reflecting the early onset and severe progression of AxD in pediatric populations. Participants were randomized in a 2:1 ratio to receive ZANVASTRO or control for a 60-week double-blind treatment period. The study included two dose cohorts, 25 mg and 50 mg, with the 50 mg dose cohort analyzed as the pivotal dose cohort, with dosing every 12 weeks. At week 60, eligible participants entered a 60-week open-label treatment period, followed by a 120-week open-label long-term extension period. During the long-term extension, participants in the 25 mg dose cohort transitioned to the 50 mg dose cohort. Participants in countries where zilganersen has not been or is not commercially available can continue to receive zilganersen treatment through a 240-week extended long-term extension period, which includes 20 additional doses, followed by a 28-week post-treatment follow-up period. The primary endpoint was percent change from baseline in gait speed as assessed by the 10-Meter Walk Test (10MWT), an assessment of functional mobility, at the end of the double-blind treatment period. Key secondary endpoints include patients' self-identified Most Bothersome Symptom (MBS) Score, change from baseline in Patient Global Impression of Severity (PGIS) Score and Patient Global Impression of Change (PGIC) Score and Clinician Global Impression of Change (CGIC) Score at the end of the double-blind treatment period.

About Alexander Disease (AxD)

AxD is an ultra-rare, progressive and often fatal neurological disease that occurs in approximately 1 per 1 to 3 million people worldwide and affects a type of cell in the brain called astrocytes. Astrocytes have multiple roles in the brain including support of neurons and oligodendrocytes, which maintain the myelin sheath around nerve fibers. AxD is caused by disease-causing variants in the glial fibrillary acidic protein (GFAP) gene and is generally characterized by progressive neurological deterioration resulting in loss of functional mobility, loss of independence and the inability to control muscles for large movements, swallowing and airway protection, though symptoms can vary depending on age of onset. AxD usually leads to death within 14 - 25 years after symptom onset.

About ZANVASTROTM (zilganersen)

ZANVASTROTM (zilganersen)is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alexander disease (AxD) in pediatric and adult patients. ZANVASTRO is an RNA-targeted therapy designed to inhibit production of excess glial fibrillary acidic protein (GFAP) that accumulates as a result of pathogenic variants in the GFAP gene. For more information about ZANVASTRO, visit ZANVASTRO.com.

About Ionis Neurology

Ionis has been at the forefront of discovering and developing leading neurological disease medicines, including ZANVASTROTM (zilganersen), the only approved treatment for Alexander disease, SPINRAZA® (nusinersen), the first approved treatment for spinal muscular atrophy, WAINUA® (eplontersen), a medicine to treat hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), and QALSODY® (tofersen) for SOD1-ALS. The clinical-stage portfolio includes 12 investigational medicines, of which seven are wholly owned by Ionis. Ionis' investigational portfolio includes medicines for which there are few or no disease modifying treatments, such as rare diseases including Angelman syndrome, prion disease and multiple system atrophy, as well as more common conditions like Alzheimer's disease.

About Ionis Pharmaceuticals, Inc.

For more than three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

Ionis Forward-looking Statements

This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of ZANVASTRO, Ionis' technologies and other products in development and our expectations regarding development and regulatory milestones. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2025, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.

Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. ZANVASTROTM and Ionis Every StepTM are trademarks of Ionis Pharmaceuticals, Inc. QALSODY® and SPINRAZA® are registered trademarks of Biogen. WAINUA® is a registered trademark of the AstraZeneca group of companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260903826844/en/

Aptos [APT] surged by more than 10% in the past 24 hours, at press time, with daily trading volume surpassing $109 million.

Apart from the technical breakout, the altcoin’s gains were being fueled by a continuous supply crunch since its fee switch. Here is how reduced supply influenced the rally:

Decoding Aptos token burns after the 10x fee increase In the past seven days, RWA net flows have driven Aptos’s network activity. In fact, Aptos ranked second with $145 million, closely behind Ethereum [ETH] at $149 million.

Additionally, the number of transactions and active addresses showed participants were returning to the chain. On the 3rd of September, Active Addresses were 57,047, while transactions surged beyond 16 million.

Source: DefiLlama From the activity data, the chain continues to accrue revenue, with average transaction fees standing at $0.0005 since the 10x fee increase.

These fees are used to buy back APT and burn them, reducing the circulating supply. That is, 1523K APT were permanently burned in the last 30 days, a total of 1.7 million tokens since mainnet. Hence, the annualized burn rate is 1.8 million tokens, as per Aptos’s post on X.

Can APT’s price hold its gains? On the charts, APT broke out for the second time from a descending trend channel. The altcoin had traded back into the pattern on the 25th of August after losing support at $0.576. It reversed at the mid-level of the channel, where it made a double bottom at $0.523.

Currently, APT is surging toward equalling August’s peak above $0.71. The RSI Divergence is supporting the projection, as it indicates bulls are still buying.

Source: APT/USDT on TradingView However, the Net Volume shows that about 340K APT were sold in the most recent session. This data hinted at weakening buyer momentum, even though the RSI was overbought.

Thus, a challenge existed at $0.65, which was a short-term resistance below $0.71.

What to expect from APT’s upcoming token unlocks? Meanwhile, stronger bearish signals from routine unlocks could add to the mid-selling pressure.

As per Tokenomist, about 11.31 million APT worth $6.88 million would be added to the circulating supply in a week’s time. This amount was equivalent to 0.65% of the released supply.

Source: Tokenomist Therefore, Aptos faces downside risk from the looming unlock, as this massive release dwarfs the small supply burned in a month.

Final Summary Aptos surged by over 10% as the altcoin priced in the burning of more than 152.9K APT tokens.  APT broke out of the channel for the second time, but bulls are facing selling pressure in a week’s time. 

Douglas Emmett, Inc. (NYSE: DEI), a real estate investment trust (REIT), announced today that its Board of Directors has declared a quarterly cash dividend on each share of its common stock of $0.19, or $0.76 on an annualized basis, to be paid on October 15, 2026 to shareholders of record as of September 30, 2026.

About Douglas Emmett, Inc.

Douglas Emmett, Inc. (DEI) is a fully integrated, self-administered and self-managed real estate investment trust (REIT), and one of the largest owners and operators of high-quality office and multifamily properties located in the premier coastal submarkets of Los Angeles and Honolulu. Douglas Emmett focuses on owning and acquiring a substantial share of top-tier office properties and premier multifamily communities in neighborhoods that possess significant supply constraints, high-end executive housing and key lifestyle amenities. Please visit our website at www.douglasemmett.com for more information about Douglas Emmett.

Safe Harbor Statement

Except for the historical facts, the statements in this press release regarding Douglas Emmett’s business activities are forward-looking statements based on the beliefs of, assumptions made by, and information currently available to us about known and unknown risks, trends, uncertainties and factors that are beyond our control or ability to predict. Although we believe that our assumptions are reasonable, they are not guarantees of future performance and some will inevitably prove to be incorrect. As a result, our actual future results can be expected to differ from our expectations, and those differences may be material. Accordingly, investors should use caution in relying on forward-looking statements to anticipate future results or trends. For a discussion of some of the risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in our Annual Report on Form 10-K for 2025, filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260903420079/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

SUI rebounded strongly on September 3, 2026, after a period of weakness in late August. Analyst Ali Martinez flagged a potential reversal signal, while Kravata, a regulated stablecoin payments provider, launched a new Sui-based payments system for its Latin American customers.

SUI price surges on renewed volumeAt the time of reporting, SUI was trading at $0.7668, representing a 7.54% daily increase. The trading volume also showed a significant rise, climbing by 49.43% within a day to reach $578.04 million. Over the past week, SUI gained 0.56%, according to data from CoinMarketCap.

This renewed activity comes as traders and analysts highlight technical and fundamental factors supporting the latest move.

Technical indicators and analyst outlookAli Martinez pointed to a TD Sequential “9” bullish pattern on SUI’s daily chart, noting that it signaled a possible trend reversal after a phase of persistent declines. The indicator, commonly used to assess trend exhaustion, appeared as SUI found support between $0.70 and $0.72 following the August correction.

The TD Sequential indicator identifies potential reversal points after a prolonged price move. A “9” setup can suggest that selling pressure is waning, but a confirmed uptrend requires further price action and momentum.

Buyers repeatedly stepped in around the $0.70 support area, helping to stabilize SUI and limit additional declines. Martinez noted that the next phase may see a recovery spanning one to four daily candlesticks, depending on market dynamics.

Sustained accumulation in the $0.70 to $0.73 range could drive SUI’s price higher, with targets at $0.79 and $0.85 if support holds, according to analyst BitGuru.

A close below this support would weaken the recovery trend, with volume and a break above resistance levels still needed for stronger bullish confirmation.

IndicatorCurrent ReadingResistance/TargetPrice$0.7668$0.79 / $0.85Support$0.70 – $0.73Volume$578.04 millionMomentum indicators and ecosystem developmentTradingView data showed the Relative Strength Index (RSI) at 55.62, holding above the neutral 50 level but below the moving average of 56.69. While this level does not indicate overbought conditions, it suggests moderate bullish momentum for SUI.

The Moving Average Convergence Divergence (MACD) line registered at 0.0089, slightly below the signal line of 0.0115, with a histogram value of -0.0026. This points to lingering short-term bearish pressure on the daily chart.

On the ecosystem front, Kravata announced its regulated stablecoin payments infrastructure is now live on Sui. The Latin America-focused company stated on September 2, 2026, that its solution enables approximately five million customers to perform stablecoin transactions, make payments, and manage global wallets—all with zero gas fees and settlement within seconds.

Mini dictionary: Kravata, a regulated stablecoin protocol, provides digital payment solutions tailored for the Latin American market, allowing users to conduct stablecoin transactions and manage digital wallets with no transaction fees.

Sui’s official account also highlighted the instant settlement capabilities and integration for Latin American users, boosting regional adoption and creating new payment use cases for SUI.

Sui’s official post indicated that Kravata now offers regulated stablecoin infrastructure for Latin America, enabling instant money transfers, payouts, and global accounts with zero gas fees for five million users.

Observers indicate that this integration could strengthen SUI’s use case as it attempts to maintain its price recovery. Market participants are closely watching key support areas, volume, and resistance zones for the next move.

Robinhood (HOOD +16.57%) shares were up about 15% as of this writing Thursday, at about $123.

The jump followed a wave of analyst notes and a record day on its own new blockchain network. Morgan Stanley upgraded the stock Tuesday to overweight from equal weight and lifted its price target to $150 from $124, and more bullish notes followed this week.

Morgan Stanley analyst Michael Cyprys argued that Robinhood's expanding product lineup is producing more activity and more revenue per customer. In plain terms, they're arguing Robinhood is no longer just a trading app.

And Robinhood itself put a number on that idea in late July: 13 business lines that have each reached $100 million or more in annualized revenue.

Since then, network data suggests a 14th has joined the list, and it didn't exist three months ago.

Image source: Getty Images.

The count holds upRobinhood's second-quarter report, released in late July, showed record revenue of $1.31 billion, up 32% year over year, and net income up 48% (helped by one-time investment gains). Chief financial officer Shiv Verma said the results reflected the company's product pace, with "Robinhood Legend and the Credit Card business joining our growing roster of now thirteen different business lines that have reached $100 million-plus in annualized revenues."

I count 13 lines in the 10-Q's revenue table that annualize above $100 million (anything above $25 million in the quarter). They span options, event contracts, cryptocurrencies, and equities, five interest-based lines led by margin lending, Gold subscriptions, proxy services, and two catch-all "other" buckets. The company's list is built on products rather than filing line items (Robinhood Legend doesn't get its own row), but both counts land at 13.

Lines can fall off the list, too. Securities lending was above the bar a year ago, at $54 million in the quarter, and produced just $10 million in this one.

How big is the newest line?The 14th didn't appear in any of those documents. It barely existed when they were filed.

Robinhood Chain, the company's own blockchain network built for real-world assets such as tokenized stocks, went live on July 1 -- one day after the second quarter ended.

Not only did the network set a fee record of about $3.8 million on Tuesday, but it also collected more than the Ethereum and Base networks that day. It broke that record Wednesday at about $4.5 million, according to DefiLlama data. Its average daily fee pace over the past 30 days now annualizes to about $179 million.

That $179 million needs two adjustments. Robinhood sends about 10% of the network's revenue after costs back to the Arbitrum ecosystem, whose technology the chain runs on. And annualizing the hottest stretch of a two-month-old network is generous math -- the chain's lifetime revenue through the start of this week was only about $10 million, and daily fees that spike may fade just as quickly.

Even with those adjustments, the pace arguably clears $100 million. Zoom out, though, and it amounts to about 2% of Robinhood's revenue pace of roughly $5.2 billion. Big enough to make the list, and far too small to carry the company.

Order flow still supplies a third of revenueHow much of the company still runs on its best-known business, routing customers' stock and options trades to market makers?

In the second quarter, equities produced $129 million of transaction revenue and options $342 million. Together, the two lines produced about 36% of total revenue.

But that share isn't shrinking. A year earlier, the two supplied about a third of revenue as well, and both are still growing. Equities transaction revenue nearly doubled year over year, while options revenue rose 29%.

The diversification is happening elsewhere. Cryptocurrency trading revenue was $160 million a year ago, $134 million in the first quarter, and $100 million in the second -- a steady step down. Meanwhile, event contracts (Robinhood's prediction-markets business) went from $10 million a year ago to $104 million in the first quarter and then $156 million in the latest one, and margin interest nearly doubled to $215 million.

Premium Feature

Moneyball Superscore

81/100

Today's Change

(

16.57

%) $

17.73

Current Price

$

124.72

Ultimately, the case under this week's upgrades mostly checks out against Robinhood's own disclosures. The valuation is where I hesitate.

After Thursday's jump, shares cost about 43 times the earnings analysts expect the company to generate next year, while brokerage peer Charles Schwab costs about 14 times its own next-year forecast. Of course, some premium is deserved. After all, Schwab isn't growing revenue 32% or adding two new $100 million lines in a single quarter.

However, higher price targets aren't a reason to buy a stock, and neither is a 15% pop. I wouldn't sell a business that keeps adding $100 million lines. But I wouldn't chase the growth stock here, either. I view it as a hold for now.

THE WOODLANDS, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 409 homes in August 2026, including 9 currently or previously leased single-family rental homes. This represents a 9.9% increase compared to 372 homes closed in August 2025.

As of August 31, 2026, the Company had 153 active selling communities.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

CONTACT:
Joshua D. Fattor
Executive Vice President of Finance and Capital Markets
Head of Investor Relations
(281) 210-2586
[email protected]

Samsara Inc. (IOT) Q2 2027 Earnings Call September 3, 2026 5:00 PM EDT

Company Participants

Sanjit Biswas - Co-Founder, CEO & Chairman
Dominic Phillips - Executive VP & CFO

Conference Call Participants

Dylan Becker - William Blair & Company L.L.C., Research Division
Michael Turrin - Wells Fargo Securities, LLC, Research Division
Aleksandr Zukin - Wolfe Research, LLC
Matthew Hedberg - RBC Capital Markets, Research Division
Matthew Martino - Goldman Sachs Group, Inc., Research Division
S. Kirk Materne - Evercore ISI Institutional Equities, Research Division
Matthew Bullock - BofA Securities, Research Division
Nicholas Altmann - BTIG, LLC, Research Division
Mark Schappel - Loop Capital Markets LLC, Research Division
Jason Celino - KeyBanc Capital Markets Inc., Research Division
Isabella Camaj - JPMorgan Chase & Co, Research Division

Presentation

Unknown Executive

[Presentation]

Good afternoon. Welcome to Samsara's Second Quarter Fiscal 2027 Earnings Call. I'm Marty Winick, Director of Finance and Strategy at Samsara. Joining me today are Samsara's Chief Executive Officer and Co-Founder, Sanjit Biswas; and our Chief Financial Officer, Dominic Phillips. In addition to our prepared remarks on this call, additional information can be found in our shareholder letter, press release, investor presentation and SEC filings on our Investor Relations website at investors.samsara.com.

The matters we'll discuss today include forward-looking statements. Actual results may differ materially from those contained in the forward-looking statements and are subject to risks and uncertainties described more fully in our SEC filings. Any forward-looking statements that we make on this call are based on assumptions as of today, September 3, 2026, and we undertake no obligation to update these statements as a result of new information or future events unless required by law.

During today's call, we will discuss our second quarter fiscal 2027 financial results. We'd like to point out that the company reports non-GAAP results in addition to and not as a substitute for or superior

Planet Labs PBC (PL) Q2 2027 Earnings Call September 3, 2026 5:00 PM EDT

Company Participants

Cleo Palmer-Poroner - Director of Investor Relations
William Marshall - Co-Founder, CEO & Chairman of the Board
Ashley Whitfield Johnson - President & CFO

Conference Call Participants

Xin Yu - Deutsche Bank AG, Research Division
John Godyn - Citigroup Inc., Research Division
Mike Latimore - Northland Capital Markets, Research Division
Trevor Walsh - Citizens JMP Securities, LLC, Research Division
Ryan Koontz - Needham & Company, LLC, Research Division
Michael Filatov - Joh. Berenberg, Gossler & Co. KG, Research Division
Daniel Hibshman - Craig-Hallum Capital Group LLC, Research Division
Noah Poponak - Goldman Sachs Group, Inc., Research Division
Kyle Benvenuto - Morgan Stanley, Research Division
Gregory Pendy - Clear Street LLC., Research Division
Gabriel Flouret - Cantor Fitzgerald & Co., Research Division
Christopher Quilty - Quilty Space Inc., Research Division

Presentation

Operator

Thank you for joining us, and welcome to the Planet Labs PBC Second Quarter of Fiscal Year 2027 Earnings Call. [Operator Instructions]

I will now hand the conference over to Cleo Palmer-Poroner, Director of Investor Relations.

Cleo Palmer-Poroner
Director of Investor Relations

Thanks, operator, and hello, everyone. I'm joined by Will Marshall and Ashley Johnson, who will provide a recap of our results and discuss our current outlook. We encourage everyone to please reference the earnings press release and earnings update presentation for today's call, which are available on our Investor Relations website.

Before we begin, we'd like to remind everyone that we will make forward-looking statements related to future events or our financial outlook. Any forward-looking statements are based on management's current outlook, plans, estimates, expectations, and projections. The inclusion of such forward-looking information should not be regarded as a representation by Planet that future plans, estimates, or expectations will be achieved. Such forward-looking statements are subject to various risks and uncertainties and assumptions as detailed in our SEC filings, which can be found

–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines–

–New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)–

–Improvements in quality of life were demonstrated through 28 months of treatment–

–Zorevunersen generally well tolerated, with some patients treated for more than 5 years–

–Data from the global, pivotal Phase 3 EMPEROR study anticipated in Q3 2027 to complete the planned rolling U.S. NDA submission to the FDA–

BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures as well as significant cognitive and behavioral impairments.

Data presented at EEC represent more than 5 years of clinical experience with zorevunersen in patients with Dravet syndrome, including two Phase 1/2a and ongoing open-label extension studies (OLEs). Four-year OLE results showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior. A new exploratory sub-analysis also showed substantial reductions in the most severe seizure types, which are the leading risk factor for sudden unexpected death in epilepsy (SUDEP)1. SUDEP is the primary cause of premature death in Dravet syndrome2, and up to 20% of children and adolescents with the disease die before reaching adulthood3. An additional sub-analysis presented at EEC demonstrated substantial improvements in quality of life through 28 months in the OLEs. Zorevunersen continues to be generally well tolerated in the OLEs.

“Seizures are the most acute symptom of Dravet syndrome but the disease affects nearly every aspect of a child’s development, from their ability to communicate with loved ones to skills like dressing and feeding themselves,” said Helen Cross, MB ChB, Ph.D., Professor, The Prince of Wales’s Chair of Childhood Epilepsy and Director of University College London Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology at Great Ormond Street Hospital. “The continuing improvements in cognition and behavior shown in these studies suggest zorevunersen has the potential to narrow the developmental gap between these children and their neurotypical peers, helping them gain more independence and participate in experiences that many thought might never be possible. Taken together, the data from studies of zorevunersen offer hope for a very different future for people living with Dravet syndrome and their families.”

The global, pivotal Phase 3 EMPEROR study is underway to evaluate the efficacy and safety of zorevunersen. Enrollment has completed in the planned primary analysis population, which will evaluate zorevunersen compared to sham administered via lumbar puncture (LP) in 162 patients enrolled in the U.S., U.K. and Japan. A Phase 3 data readout is anticipated in the third quarter of 2027 to complete the planned rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2027. Enrollment in Europe has also completed with 34 participants enrolled.

Summary of Data from the Phase 1/2a and OLE Studies Presented at EEC

4-year OLE data: Following treatment in the Phase 1/2a studies, 93% (75/81) of eligible patients continued treatment in the OLEs. As of the 4-year data cutoff, 77% (58/75) of patients remained in these studies. Patients receiving zorevunersen on top of standard anti-seizure medicines (ASMs) continued to experience durable reductions in seizures and ongoing improvements in cognition and behavior. Statistically significant improvements in cognition and behavior were demonstrated at 1, 2, 3 and 4 years of treatment compared to OLE baseline.
Severe seizure analysis: Patients with Dravet syndrome experience frequent, prolonged and refractory seizures. Compared with the general epilepsy population, patients with Dravet syndrome have a significantly increased risk of SUDEP2. Seizures are classified based on severity, with generalized tonic-clonic (GTC), focal-to-bilateral tonic-clonic (focal-to-BTC) and tonic-clonic seizures of unknown origin considered the most severe and correlated with the highest morbidity and mortality in people with epilepsy1. Substantial reductions in GTC and focal-to-BTC seizures were demonstrated through 3 years of the OLEs, compared to Phase 1/2a baseline, in patients treated with zorevunersen on top of standard of care ASMs.
Quality of life analysis: Patients experienced substantial improvements in quality of life through 28 months in the OLEs, compared to Phase 1/2a baseline, as measured by EuroQol Visual Analog Scale (EQ-VAS, a component of the Euro-Qol-5D Youth). EQ-VAS is a validated measure of overall health status ranging from 0 to 100 (worst to best imaginable health) and provides insight into the real-world impact of zorevunersen on patients with Dravet syndrome and their families. “Up to 20% of children and adolescents with Dravet syndrome die before reaching adulthood, and SUDEP is the primary cause,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics. “These data are especially meaningful because they show substantial reductions in the severe seizures most strongly correlated with SUDEP and demonstrate continuing improvements in the debilitating neurodevelopmental aspects of the disease. Together with ongoing improvements in quality of life, these data increase our confidence in what zorevunersen may one day deliver for the Dravet community.”

“For patients with a chronic disease like Dravet syndrome, safety and tolerability are critically important,” said Stephanie Fradette, Pharm.D., Head of the Rare Neurology Development Unit at Biogen. “The ongoing open-label extension studies will continue to grow the body of evidence shaping our understanding of zorevunersen’s long-term safety as well as its potential to address the underlying genetic cause of Dravet syndrome and improve outcomes for patients. We look forward to results from the Phase 3 EMPEROR study next year.”

Summary of Zorevunersen Safety Data

Zorevunersen continues to be generally well tolerated, with some patients treated for more than 5 years in the Phase 1/2a and ongoing OLE studies. As of July 31, 2026, more than 930 doses have been administered.Elevated CSF protein lab values occurred in approximately 94% of patients, of which 59% have been classified as a treatment-emergent adverse event. Importantly, no serious or severe clinical manifestations have been associated with CSF protein elevations. There have been no reports of hydrocephalus. About Dravet Syndrome
Dravet syndrome is a severe developmental and epileptic encephalopathy (DEE) characterized by recurrent seizures as well as significant cognitive and behavioral impairments. Most cases of Dravet are caused by mutations in one copy of the SCN1A gene, leading to insufficient levels of NaV1.1 protein in neuronal cells in the brain. Even when treated with the best available anti-seizure medicines (ASMs), up to 57 percent of patients with Dravet syndrome do not achieve ≥50 percent reduction in seizure frequency. Complications of the disease often contribute to a poor quality of life for patients and their caregivers. Developmental and cognitive impairments often include intellectual disability, developmental delays, movement and balance issues, language and speech disturbances, growth defects, sleep abnormalities, disruptions of the autonomic nervous system and mood disorders. Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP; up to 20 percent of children and adolescents with Dravet syndrome die before adulthood due to SUDEP, prolonged seizures, seizure-related accidents or infections3. Dravet syndrome occurs globally and is not concentrated in a particular geographic area or ethnic group. Currently, it is estimated that up to 38,000 people are living with Dravet syndrome in the U.S. (~16,000), UK, EU-4 and Japan4. There are no approved disease-modifying therapies for people living with Dravet syndrome.

About Zorevunersen
Zorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the unaffected (wild-type) copy of the SCN1A gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function in the SCN1A gene, and China’s Center for Drug Evaluation has granted zorevunersen Breakthrough Therapy Designation. Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights. Zorevunersen is currently in clinical development, and its safety and efficacy have not been evaluated by any regulatory authority.

About the Phase 1/2a and Open-Label Extension Studies
Two Phase 1/2a open-label, multicenter studies evaluated the effects of zorevunersen in patients with highly refractory Dravet syndrome ages 2 to 18 years (N=81). Primary endpoints were the safety profile, plasma pharmacokinetics (PK) and exposure in cerebrospinal fluid (CSF) of single and multiple doses of zorevunersen. Secondary endpoints included percentage change from baseline in major motor seizure frequency, overall clinical status (a measure of patients’ overall functioning) and quality of life. The ADMIRAL Phase 1/2a study included an exploratory endpoint to evaluate changes in neurodevelopmental status (cognition & behavior) as measured by Vineland Adaptive Behavior Scales, Third Edition (Vineland-3). The Phase 1/2a studies were completed in November 2023. Following treatment in the Phase 1/2a studies, eligible patients continued treatment with zorevunersen every four months in one of two OLEs. There was at least a 6-month gap between the last dose administered in the Phase 1/2a studies and the first dose administered in the OLEs. The primary endpoints are the safety profile of multiple doses of zorevunersen. Secondary endpoints include PK parameters, percentage change from baseline in major motor seizure frequency, change in overall clinical status, and change from baseline in quality of life. Exploratory endpoints include changes in neurodevelopment status as measured by Vineland-3. Results from the Phase 1/2a and OLE studies were published in The New England Journal of Medicine (NEJM) in March 2026. The OLE studies are ongoing.

About the Phase 3 EMPEROR Study
The Phase 3 EMPEROR Study (NCT06872125) is a global, double-blind, sham-controlled study evaluating the efficacy, safety and tolerability of zorevunersen in children ages 2 to <18 with Dravet syndrome with a confirmed variant in the SCN1A gene not associated with gain-of-function. Stoke completed enrollment in the United States, United Kingdom and Japan in June 2026, and a data readout is anticipated in the third quarter of 2027 to support the submission of a rolling New Drug Application (NDA) to the FDA. Enrollment in Europe completed in August 2026. Enrollment is currently underway in China and is anticipated to complete in the second half of 2026. Participants in EMPEROR are randomized 1:1 to receive either zorevunersen via intrathecal administration or a sham comparator for a 52-week treatment period following an 8-week baseline period. Following the completion of the study treatment period, eligible participants will be offered ongoing treatment with zorevunersen as part of an open-label period of the study. The primary endpoint of the study is percent change from baseline in major motor seizure frequency at week 28 in patients receiving zorevunersen as compared to sham. The key secondary endpoints are the durability of effect on major motor seizure frequency and improvements in behavior and cognition as measured by Vineland-3 subdomains, including expressive communication, receptive communication, interpersonal relationships, coping skills and personal skills. Additional endpoints include safety, Clinician Global Impression of Change (CGI-C), Caregiver Global Impression of Change (CaGI-C) and the Bayley Scales of Infant Development (BSID-IV). For more information, visit https://clinicaltrials.gov/study/NCT06872125.

About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke’s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke’s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow us on LinkedIn.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, Instagram, LinkedIn, X, YouTube.

Stoke Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the ability of zorevunersen to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior and cognition at the indicated dosing levels or at all; the potential benefits, safety and efficacy of zorevunersen; the design, timing and expected progress of clinical trials, data readouts, regulatory meetings, regulatory decisions and other presentations; and the potential timing for initiation and completion of the U.S. NDA submission to the FDA. Statements including words such as “plan,” “potential,” “will,” “continue,” “expect,” or similar words and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause Stoke’s results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: Stoke’s ability to advance, obtain regulatory approval and ultimately commercialize its product candidates; that if Biogen were to breach or terminate the collaboration, Stoke would not obtain the anticipated financial or other benefits; the possibility that Stoke and Biogen may not be successful in their development of zorevunersen and that, even if successful, they may be unable to successfully commercialize zorevunersen; positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials; Stoke’s ability to protect its intellectual property; Stoke’s ability to fund development activities and achieve development goals into 2028; and the other risks and uncertainties described under the heading “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025, its quarterly reports on Form 10-Q, and the other documents it files with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Stoke undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Biogen Safe Harbor
This news release contains forward-looking statements, including, among others, relating to: the potential clinical effects of zorevunersen; the potential for zorevunersen to improve outcomes for patients with Dravet syndrome; the expected timing of Phase 3 study results; the potential benefits, safety and efficacy of zorevunersen; potential regulatory discussions, applications, submissions and approvals and the timing thereof; the potential treatment of the underlying genetic cause of Dravet syndrome; the anticipated benefits, risks and potential of Biogen's collaboration arrangements with Stoke Therapeutics; the potential of Biogen's commercial business and pipeline programs, including zorevunersen; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Biogen Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References:

Beniczky, S. et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025; 1804–1823.Shmuely, S. et al. Mortality in Dravet syndrome: A review, Epilepsy & Behavior. 2016: (Pt A) 69-74.Symonds, J. et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain. 2021;144(9):2879-2891.Based on Stoke Therapeutics’ preliminary estimates, which scaled annual incidence to prevalence using country-specific live birth rates over the past 85 years and adjusted for Dravet-specific mortality. The estimate is based on incidence rates published by Wu et al., Pediatrics, 2015. Stoke Media & Investor Contacts:
Susan Willson
Vice President, Corporate Communications
[email protected]
415-509-8202

Investor Relations
[email protected]

Biogen Media Contact:
Madeleine Shin
[email protected]
781-464-3260

Biogen Investor Contact:
Tim Power
[email protected]
781-464-2442

Progressive (PGR - Free Report) closed at $223.91 in the latest trading session, marking a +1.14% move from the prior day. This change outpaced the S&P 500's 1.06% gain on the day. Elsewhere, the Dow gained 1.18%, while the tech-heavy Nasdaq added 1.4%.

The stock of insurer has risen by 4.05% in the past month, leading the Finance sector's gain of 0.85% and the S&P 500's gain of 2.46%.

Investors will be eagerly watching for the performance of Progressive in its upcoming earnings disclosure. In that report, analysts expect Progressive to post earnings of $3.98 per share. This would mark a year-over-year decline of 1.73%. Alongside, our most recent consensus estimate is anticipating revenue of $23.29 billion, indicating a 4.83% upward movement from the same quarter last year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $17.74 per share and revenue of $92.26 billion, which would represent changes of -2.79% and +6.12%, respectively, from the prior year.

Any recent changes to analyst estimates for Progressive should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.42% increase. Progressive currently has a Zacks Rank of #3 (Hold).

In the context of valuation, Progressive is at present trading with a Forward P/E ratio of 12.48. This valuation marks a premium compared to its industry average Forward P/E of 11.55.

It is also worth noting that PGR currently has a PEG ratio of 2.95. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. PGR's industry had an average PEG ratio of 1.71 as of yesterday's close.

The Insurance - Property and Casualty industry is part of the Finance sector. With its current Zacks Industry Rank of 60, this industry ranks in the top 25% of all industries, numbering over 250.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against OSI Systems, Inc. (“OSI” or the “Company”) (NASDAQ: OSIS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired OSI securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.

[LEARN MORE ABOUT THE INVESTIGATION]

What Happened?

On August 20, 2026, OSI reported its fourth quarter 2026 and full-year 2026 financial results, revealing fourth quarter revenue that fell short of analysts’ expectations by 8.5%, with sales falling 4.1% year-on-year to $484.1 million. The Company attributed the revenue shortfall to Security division delivery disruptions caused by conflicts in the Middle East, stating, “these results were affected by the timing of approximately $50 million of planned Security deliveries that moved beyond our June 30th fiscal year-end because of conflict-related delays and site access constraints in the Middle East.” On this news, OSI’s stock price fell $11.36, or 5.21%, to close at $206.73 per share on August 21, 2026.

What Should I Do?

At this stage, no lawsuit has been filed. The investigation is ongoing to determine whether claims may be brought under federal securities laws.

If you purchased or otherwise acquired OSI securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[LEARN MORE ABOUT SECURITIES CLASS ACTIONS]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP                                                              
Lauren Molinaro, Esq.
212-699-1171
https://www.kmllp.com
https://securitiesleadplaintiff.com/
[email protected]

Guidewire Software (GWRE - Free Report) came out with quarterly earnings of $0.99 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.32%. A quarter ago, it was expected that this provider of software to the insurance industry would post earnings of $0.79 per share when it actually produced earnings of $0.82, delivering a surprise of +3.8%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Guidewire Software, which belongs to the Zacks Internet - Software industry, posted revenues of $411.09 million for the quarter ended July 2026, surpassing the Zacks Consensus Estimate by 2.20%. This compares to year-ago revenues of $356.57 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Guidewire Software shares have lost about 4.1% since the beginning of the year versus the S&P 500's gain of 12%.

What's Next for Guidewire Software?While Guidewire Software has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Guidewire Software was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.83 on $381.97 million in revenues for the coming quarter and $4.07 on $1.68 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software is currently in the top 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Oddity Tech (ODD - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on September 9.

This online retailer of cosmetics and beauty products is expected to post quarterly earnings of $0.12 per share in its upcoming report, which represents a year-over-year change of -87%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Oddity Tech's revenues are expected to be $174.8 million, down 27.5% from the year-ago quarter.

EPC Power's Intelligent Power Conversion Solutions Directly Address the Fundamental Challenges of an Aging U.S. Power Grid Supporting the Energy Demand Supercycle and the AI Era

, /PRNewswire/ -- EPC Power Corp. ("EPC Power"), a leading North American designer and manufacturer of high-performance, software-defined power conversion solutions for data centers, utility-scale energy storage, and microgrids, today announced it has entered into a definitive agreement to be acquired by Flex (NASDAQ: FLEX) for $4.4 billion. The transaction is subject to customary closing conditions, including the receipt of required regulatory approvals, and is expected to close in the fourth quarter of 2026. Building on the two companies' existing collaboration, EPC Power will become, upon closing, a business within Flex's Cloud and Power Infrastructure segment.

The transaction brings EPC Power's differentiated power conversion technology platform to Flex's broad portfolio of power and thermal management technologies for mission-critical applications. EPC Power's next-generation 800-volt data center power architectures, including digital rectifiers and solid-state transformers, enable more efficient power delivery for higher-density AI infrastructure and extend leadership with Flex into an integrated grid-to-chip portfolio. The combined company is positioned to help solve one of the most pressing challenges facing the technology and energy industries today: delivering the fast, resilient and secure power that AI data centers need while supporting stable grid operations amid a generational surge in power demand.

"What we accomplished over the last four years demonstrates the power of strong partnerships and a shared commitment to innovation. Together with Goldman Sachs Alternatives and Cleanhill Partners, EPC Power emerged as a U.S. technology leader in power conversion solutions that enable the next generation of data centers, AI computing, and grid modernization. We expanded our domestic manufacturing footprint nearly tenfold, strengthening America's industrial base and reinforcing the critical role of U.S. innovation in powering the future economy. This is only the beginning of what EPC Power can accomplish," said Jim Fusaro, Chief Executive Officer of EPC Power.

"This is a landmark moment for EPC Power and every colleague who helped build this company. When we founded EPC Power, we set out to solve the hardest problems in power electronics, and our partnership with Goldman Sachs Alternatives and Cleanhill Partners enabled us to solve those problems for mission-critical infrastructure globally," added Devin Dilley, Co-Founder, President and Chief Innovation Officer of EPC Power.

Solving the Binding Constraint on AI Infrastructure

Power availability has become the gating factor for data center growth. As AI workloads drive unprecedented increases in power density, resilience and control requirements, operators must address speed-to-power and load volatility, where the rapid, large-swing power draw of AI training and inference clusters can destabilize the local grid.

EPC Power's technology is purpose-built for these conditions. The company's solutions, including its Agile Grid Forming™ technology, deliver performance and reliability that enables on-site energy storage, microgrid and grid-support configurations for data centers, which allow operators to energize capacity faster and ride through grid instability. Grid operators and utilities benefit from stronger reliability and power quality across their networks.

"We are immensely proud of our partnership with Jim, Devin and the EPC Power team that saw the company launch new product platforms, increase domestic U.S. manufacturing and partner with customers to solve novel challenges in AI power architecture. EPC Power plays a critical role in supporting grid reliability and speed to power during a period of growing concerns around energy security. We wish Flex and the EPC team continued success during their stage of growth," said Alexander Mass, Global Co-Head of Energy Transition Investing within Private Equity at Goldman Sachs Alternatives.

"As grid resilience and data center power demand have converged into one of the defining challenges of the next decade, it has been a privilege to support EPC Power's operational and commercial scale-up into a global platform positioned at the center of those megatrends," added Eddie Sigman, Investor within Private Equity at Goldman Sachs Alternatives.

"We first invested in EPC Power in 2021 because we believed power conversion would become a critical enabling technology as renewable generation, grid modernization and digital infrastructure converged. That conviction came well before the extraordinary growth in power demand driven by AI. Since then, we have had the privilege of working closely with Jim, Devin and the EPC team as the company grew, expanded its U.S. manufacturing footprint and created high-quality jobs in the U.S. We are proud to have supported EPC from an early stage and, in its next phase, alongside Goldman Sachs Alternatives as the business entered a new period of growth. Seeing what the team has built over the past five years has been incredibly rewarding, and we believe Flex is the right partner for EPC's next chapter," said Ash Upadhyaya and Rakesh Wilson, Managing Partners at Cleanhill Partners.

Goldman Sachs & Co. LLC. and J.P. Morgan Securities LLC served as financial advisors, and Vinson & Elkins LLP served as legal counsel, to EPC Power and its controlling shareholders Goldman Sachs Alternatives and Cleanhill Partners.

About EPC Power

EPC Power Corp. (EPC Power) is a power solutions platform that develops high-performance power conversion systems for mission-critical applications, including data centers, utility-scale energy storage, and microgrids. EPC Power's solutions are designed to deliver reliable, resilient, and secure energy for demanding applications, including AI-driven workloads and grid stability use cases supported by EPC Power's Agile Grid Forming™ technology. Visit EPCPower.com for more information.

About Flex

Flex (Reg. No. 199002645H) is the manufacturing partner of choice that helps leading brands design, build, and manage products that improve the world. With a global footprint spanning 30 countries, Flex delivers advanced manufacturing and supply chain solutions, innovative products and technology, and lifecycle services that support customers from concept to scale. In the AI era, Flex is helping customers accelerate data center deployment by solving power, heat, and scale challenges through cutting-edge power and cooling technology and scalable IT infrastructure solutions. For information about Flex's intent to spin off its Cloud and Power Infrastructure portfolio, visit: https://flex.com/transaction-resources 

About Private Equity at Goldman Sachs Alternatives

Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $706 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, venture capital, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.

The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world's leading institutions, financial advisors and individuals. Goldman Sachs has more than $4.0 trillion in assets under supervision globally as of June 30, 2026.

Established in 1986, Private Equity at Goldman Sachs Alternatives has invested over $75 billion since inception. The business combines a global network of relationships, unique insight across markets, industries and regions, and the worldwide resources of Goldman Sachs to build businesses and accelerate value creation across its portfolios.

Follow us on LinkedIn

About Cleanhill Partners

Cleanhill Partners is a private equity firm focused on energy transition and digital infrastructure. The firm invests in companies across power generation, energy storage, grid modernization, domestic manufacturing and related technologies that support the growing demand for reliable power.

Cleanhill works closely with management teams to help companies scale and build long-term value. The firm is led by investors and operators with more than two decades of experience across. For more information, visit www.cleanhillpartners.com.

SOURCE EPC Power

Smith & Wesson Brands, Inc. (SWBI) Q1 2027 Earnings Call September 3, 2026 5:00 PM EDT

Company Participants

Kevin Maxwell - Senior VP, General Counsel, Chief Compliance Officer & Secretary
Mark Smith - President, CEO & Director
Deana McPherson - Executive VP, CFO, Treasurer & Assistant Secretary

Conference Call Participants

Alex Ewig

Presentation

Operator

Good day, everyone, and welcome to Smith & Wesson Brands, Inc. First Quarter Fiscal 2027 Financial Results Conference Call. This call is being recorded.

At this time, I would like to turn the call over to Kevin Maxwell, Smith & Wesson's General Counsel, who will give us information about today's call. Thank you. You may begin.

Kevin Maxwell
Senior VP, General Counsel, Chief Compliance Officer & Secretary

Thank you and good afternoon. Our comments today may contain forward-looking statements. Our use of the words anticipate, project, estimate, expect, intend, believe, and other similar expressions are intended to identify forward-looking statements. Forward-looking statements may also include statements on topics such as our product development, strategies, market share, demand, consumer preferences, inventory conditions for our products, growth opportunities and trends, and industry conditions in general.

Forward-looking statements represent our current judgment about the future and are subject to risks and uncertainties that could cause our actual results to differ materially from those expressed or implied by our statements today. These risks and uncertainties are described in our SEC filing, which are available on our website, along with a replay of today's call. We have no obligation to update forward-looking statements.

We reference certain non-GAAP financial results. Reconciliations of GAAP financial measures to non-GAAP financial measures can be found in our SEC filing and in today's earnings press release, each of which is available on our website. Also, when we reference EPS, we are always referencing fully diluted EPS, and any reference to EBITDA is

Texas stopped approving additional grid hookups as bipartisan scrutiny intensifies over power, water, rural development and incentives. Summary

Meta’s massive El Paso expansion now faces a tougher political path.

Meta Platforms META, the social-media and artificial-intelligence giant, hit a Texas-sized political wall Thursday, with shares trading at $611.62. Its planned El Paso data-center campus will cost more than $10 billion, but lawmakers from both parties are turning up the pressure on Big Tech's expansion. Reuters reported that Gov. Greg Abbott wants tougher restrictions, fewer incentives and tighter limits on rural development. The state has approved no additional grid hookups since an August 3 audit. Meta has the money. Texas controls the power switch.

This is no ordinary server farm. Meta's project plan calls for one gigawatt of computing capacity, with the first phase expected online in 2028. Meta will initially occupy the entire facility. Construction could support more than 4,000 jobs at its peak, followed by approximately 300 permanent positions. That is a powerful economic pitch. But jobs alone may not overpower concerns about electricity, water and taxpayer incentives.

The disclosed investment equals at least 7.3% of Meta's $137.5 billion annual capital-expenditure midpoint, although construction will span multiple periods. The company spent $31.08 billion on capital expenditures last quarter while generating only $784 million in free cash flow. The valuation gap is hard to ignore: at $611.62, Meta trades 27.78% below its $846.92 GF Value™, pointing to substantial potential upside if its AI infrastructure bet delivers. The upside looks tempting. The spending pressure—and now the political resistance—looks just as real.

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Tesla published a form on Thursday for businesses interested in buying Cybercab fleets or providing infrastructure for its network, the latest sign that the company’s aspirations for its gold-hued autonomous vehicle stretch beyond being a robotaxi operator.

The robotaxi interest form, which was released ahead of the company’s Cybercab event in Austin, is not definitive proof that Tesla will sell its autonomous vehicles to third-party operators. But it’s certainly an indicator of where the company’s longer-term plans lie. Tesla wants to scale and it doesn’t seem to want to do it alone.

Tesla CEO Elon Musk has talked often, and for years, about building a massive fleet of low-cost robotaxis. But in the early days, those dreams centered on personally owned Tesla vehicles. As early as 2016, Musk spoke publicly about a future in which Tesla owners, equipped with self-driving software, would be able to earn money by renting out their vehicles. He stuck with that Tesla network idea for years, noting at the company’s Autonomy Day in 2019 that it would allow owners to add their autonomous vehicles to its ride-sharing app, similar to how Uber’s business model works.

“I feel very confident predicting that there will be autonomous robotaxis from Tesla next year — not in all jurisdictions because we won’t have regulatory approval everywhere,” Musk said in 2020.

That vision never materialized. Instead, the company has focused on testing, and now operating, its own fleet of robotaxis — first with Tesla Model Y vehicles and now the purpose-built Cybercab.

Until now, Tesla seemed committed to keeping its robotaxi business in-house. The interest form, which says “helps us build our robotaxi network,” suggests the company sees promise and profits in widening the circle to include third-party companies.

What that might look like, though, isn’t defined. The company asks interested parties to pick one of several possible options, including Cybercab fleet purchasing, mobility hubs and infrastructure, event collaboration, and “other.”

There are a growing number of companies jumping into the robotaxi fleet management business. For instance, Moove, an African fintech startup that initially focused vehicle financing for ride-hailing drivers, is scaling up an autonomous fleet management business. The startup, which raised $250 million last month at a $2.1 billion valuation, is the fleet operator for Waymo in Phoenix, Miami, and Las Vegas, and in the future, London. The company doesn’t own the Waymo vehicles, but its CEO told TechCrunch that it plans to.

Other autonomous fleet management companies, which Uber has partnered with in its bid to own a piece of the robotaxi market, include Avomo and New Horizon as well as larger more traditional rental car giants like Avis and Hertz.

Tesla’s welcome mat to fleet operators could encourage more small players to open up shop — helping the company saturate markets faster.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Kirsten Korosec is a reporter and editor who has covered the future of transportation from EVs and autonomous vehicles to urban air mobility and in-car tech for more than a decade. She is currently the transportation editor at TechCrunch and co-host of TechCrunch’s Equity podcast. She is also co-founder and co-host of the podcast, “The Autonocast.” She previously wrote for Fortune, The Verge, Bloomberg, MIT Technology Review and CBS Interactive.

You can contact or verify outreach from Kirsten by emailing [email protected] or via encrypted message at kkorosec.07 on Signal.

Elon Musk promised a billion humanoid robots will outproduce all of humanity within a decade, then turned around and pledged tens of thousands of new human jobs in Austin to build them. The contradiction at the center of Tesla's strategy…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Elon Musk spent this week making two claims that sit awkwardly next to each other. On September 1, he told the world that “a billion humanoid robots will be more productive than all humans combined within 10 years” and that AI will be able to do anything digital, anything that does not require shaping of atoms by hand, probably by the end of next year. Two days later, on September 3, he pledged that “Probably over 30k people working in high-paying jobs at Tesla HQ & manufacturing in Austin by 2028!”

I have been tracking Musk’s rhetoric on Optimus for the better part of two years, and this is the sharpest juxtaposition I have seen. The person forecasting the end of human labor is also promising to roughly double a human payroll in one city, and the workers he wants to hire will be building the very robots and Robotaxis designed to replace human effort elsewhere.

Austin Headcount Math and the 16,500 Baseline Tesla (NASDAQ:TSLA | TSLA Price Prediction) has not published an official Giga Texas headcount tied to this pledge. The roughly 16,500 workers currently in Austin figure comes from the tweet Musk endorsed, not from Tesla investor relations or a Texas incentive filing. Treat 30,000 as a Musk tweet target until it shows up as an audited commitment in a proxy or an 8-K. The most recent Q2 FY26 shareholder update discusses Austin capacity expansions without pinning a headcount number to them.

The Austin footprint Musk is staffing up is enormous on paper. Cybercab production began at Gigafactory Texas with engineering test drives on public roads in Q2 2026. 4680 battery cell production sits at over 40 GWh of installed Texas capacity, and Tesla has “placed equipment orders for our development fab in Austin” covering lithography-mask production, logic, memory, packaging and chip testing under one roof.

Optimus: Fremont First, Austin Bigger On the Q2 call, Musk called Optimus “the biggest product ever” and warned that “this is going to be the hardest product to scale manufacturing that we’ve ever made at Tesla because everything on the robot is new.” The Gen 3 line runs in Fremont with a target of a million units a year. Optimus 4 goes to Austin, aiming “an order of magnitude more production of Optimus 4 than Optimus 3” at roughly 10 million units a year.

If those robots ever hit dexterity parity with humans, and Musk said “an Optimus is designed to have full human dexterity”, the 30,000 Austin jobs are best understood as a construction and ramp cohort that precedes a leaner steady-state operating base. Someone has to install the lines before the lines replace them.

Cybercab Week and the Stock The jobs pledge landed during Cybercab week. Musk described the vehicle as “basically a super comfortable lounge on wheels with a great TV and epic sound”. Tesla closed at $376.37 on September 3, up 5% on the day and 15% over the past month, though shares remain down 16% year to date. Market cap sits near $1.49 trillion at a P/E around 372.

The financial backdrop for all of this is a company burning cash to build the future. Q2 FY26 revenue hit $28.24B, up 25.5% year over year, while operating income fell 56.9% to $398M and free cash flow swung negative $1.09B. CFO Vaibhav Taneja told investors “we are in a big investment cycle and expect our operating expenses largely driven by R&D to continue to grow in 2026 and beyond,” with capital expenditures expected to top $25 billion this year and debt facilities of up to $30 billion being lined up.

What to Watch Musk even joked the same afternoon that Austin in September is not a great time of year to recruit people. The serious question for TSLA holders is whether the Austin buildout produces enough Optimus and Cybercab volume by 2028 to justify a $1.49 trillion valuation, and whether those 30,000 jobs get audited in a future proxy filing or fade as a tweet. If you believe Musk that “the AI riptide is already underway”, the Austin hires are the last big human cohort Tesla needs before the robots take the line. If you do not, the pledge is a headline during Cybercab week. Either way, the SEC filings will tell us which Musk to believe.

Contact [email protected] for any questions or corrections.

Instant delivery changed consumer behavior; now Alibaba must prove warehouses can replace subsidies with returns. Summary

Faster shopping created demand before it created dependable profit.

Alibaba Group BABA, the Chinese commerce, cloud and artificial-intelligence giant, entered a tougher chapter in China's instant-retail war. After a year of coupons and delivery subsidies, the fight is shifting from winning orders to making those orders profitable. Reuters estimates the market could reach 1.2 trillion yuan, or roughly $178 billion, by year-end.

The battlefield is also getting bigger. Alibaba and its rivals are pushing beyond restaurant meals into electronics, medicine, flowers and other higher-margin products promised within an hour. That expansion demands automated warehouses, denser fulfillment networks and disciplined spending—especially after regulators reined in the industry's most aggressive promotions.

Alibaba traded at $111.135 on Sept. 3, sitting 6.88% below its GF Value estimate of $119.35 and implying roughly 7.4% upside if the shares reach that benchmark. But valuation is only part of the story. Alibaba's June-quarter release does not isolate instant-retail profitability, leaving investors with one decisive question: can higher order density and repeat purchases turn subsidy-driven demand into durable earnings?

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Officials contacted eight retailers, including Walmart, Costco and Amazon, as record beef prices intensify scrutiny. Summary

The inquiry increases scrutiny but does not accuse Walmart of antitrust violations.

Walmart WMT, the world's largest retailer, rallied nearly 2.8% to $109.015 Thursday even as Washington turned up the heat on beef pricing. Reuters reported that the Justice Department contacted eight retailers, including Walmart, Costco and Amazon, as record beef prices pushed grocery affordability deeper into the political spotlight.

This is scrutiny, not a guilty verdict. Walmart has not been accused of fixing prices, manipulating the market or violating antitrust law. The review runs alongside a separate investigation into meatpackers, widening the government's lens across the beef supply chain while leaving the immediate financial threat to Walmart unclear.

Walmart's second-quarter results packed $187.9 billion in revenue, while first-half inventory hit $61.6 billion. Grocery scale keeps shoppers coming, but stubborn food inflation can bite margins when Walmart holds prices down to defend its value crown. At $109.015, the stock sits 5.46% above its $103.37 GF Value estimate—a clear sign investors still prize Walmart's defensive power despite the regulatory noise.

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Key Takeaways HPE, AVGO, and DELL all posted strong results recently. AI-related demand has benefited each in a big way. The AI trade remains alive and well, with Hewlett Packard Enterprise (HPE - Free Report) , Broadcom (AVGO - Free Report) , and Dell Technologies (DELL - Free Report) all recently posting strong quarterly results.

AI infrastructure spending was the clear theme across all releases, with demand remaining robust for servers, networking, and custom accelerators. Still, market reactions have been mixed, indicating that expectations remain sky-high for many AI-focused names.

Let’s take a closer look at the results.

HPE Raises Its OutlookHewlett Packard Enterprise posted record quarterly revenue of $12.2 billion, reflecting 34% YoY growth. Adjusted earnings came in at $1.11 per share, climbing sharply from $0.44 in the same period last year and exceeding the Zacks Consensus EPS estimate by nearly 17%.

Cloud & AI revenue reached $9.0 billion, up 25% YoY, with Server revenue climbing 35% to $6.8 billion. Networking results were even stronger, with revenue jumping 75% to $2.9 billion. Data Center Networking revenue more than doubled, while Routing revenue climbed 270%.

Importantly, the demand picture remains bright. AI Systems orders reached $2.4 billion during the quarter, with backlog climbing to $6.8 billion. HPE also raised its FY26 revenue growth outlook to 34%-37% and now expects adjusted EPS of $3.75-$3.85. Looking further ahead, management boosted its FY27 revenue growth outlook to 13%-17%, paired with expected adjusted EPS growth of 16%-20%.

The numbers were undoubtedly positive, though supply constraints and the lower-margin nature of some AI systems remain items to keep in mind. Still, the raised outlook and favorable Zacks Rank #2 (Buy) reflect a constructive earnings picture overall.

Image Source: Zacks Investment Research

Broadcom’s AI Growth AcceleratesBroadcom delivered another monster quarter, posting $29.6 billion in revenue, up 86% YoY. Adjusted EPS of $3.32 grew 96% from the year-ago period and came in 3% above the Zacks Consensus estimate.

To little surprise, AI again stole the show. AI semiconductor revenue reached $16.7 billion, surging 221% YoY and 54% sequentially as demand for custom accelerators and networking products remained red-hot. Semiconductor Solutions revenue overall climbed 127% to $20.8 billion, while Infrastructure Software revenue rose 29% to $8.8 billion.

And the momentum isn’t expected to slow down anytime soon. Broadcom expects AI semiconductor revenue of $21.7 billion next quarter, reflecting 236% YoY growth, with total revenue forecasted at roughly $34.8 billion. Management has also outlined roughly $115 billion of AI semiconductor revenue for FY27, with the longer-term opportunity potentially reaching $230 billion in FY28.

Interestingly enough, shares traded lower following the release despite the eye-popping growth. Expectations for Broadcom have clearly become massive, making even great results a tough act to follow. AVGO currently carries a Zacks Rank #3 (Hold), with the earnings-revision picture worth watching following the release.

Image Source: Zacks Investment Research

Dell’s AI Backlog SurgesDell Technologies arguably posted the most impressive results of the group, with shares surging following the release.

Revenue climbed 58% YoY to a record $47.0 billion, while adjusted EPS of $7.04 reflected growth of more than 200% and crushed the Zacks Consensus estimate. Infrastructure Solutions Group revenue jumped 89% to $31.8 billion, with segment operating income soaring 225% to $4.8 billion.

AI-Optimized Server revenue doubled to $16.4 billion, but the order and backlog figures were perhaps even more impressive. Dell booked a record $60.9 billion of AI server orders during the quarter and exited with a massive $95 billion backlog, providing strong top line visibility.

The strength wasn’t isolated to AI, either. Traditional Servers and Networking revenue jumped 122%, Storage revenue grew 26%, and Client Solutions Group sales climbed 20%. Dell raised its FY27 revenue outlook by $25 billion to $192 billion while boosting its AI-Optimized Server revenue expectation to $74 billion from $60 billion previously.

DELL currently sports a Zacks Rank #2 (Buy), with the combination of accelerating AI demand, a huge backlog, and raised guidance providing a rock-solid near-term backdrop.

Image Source: Zacks Investment Research

Bottom Line

The latest results from Hewlett Packard Enterprise (HPE - Free Report) , Broadcom (AVGO - Free Report) , and Dell Technologies (DELL - Free Report) further strengthened the AI infrastructure growth story.

Demand remains robust across several areas of the buildout, ranging from Dell and HPE’s AI servers and networking offerings to Broadcom’s custom accelerators and networking chips. And importantly, all three provided upbeat forward-looking commentary alongside their strong quarterly growth.

Salesforce CRM , the customer-management and enterprise-software powerhouse, climbed to $264 on Thursday as Snowflake's stronger outlook reignited the software trade. Reuters reported that the cloud-data company's quarterly product revenue surged 37%, with artificial intelligence driving roughly half of its recent growth acceleration. That is fresh ammunition for Salesforce bulls: enterprise AI demand is turning into real spending.

Salesforce is already building its own AI machine. Its second-quarter results showed revenue jumping 11% to $11.3 billion, while current remaining performance obligations climbed 14% to $33.5 billion. Agentforce and Data 360 annual recurring revenue closed in on $3.9 billion, including more than $1.5 billion from Agentforce. The products are gaining traction. Now they must move the entire growth needle.

The valuation gap is hard to ignore. At $264.005, Salesforce trades 22.13% below its $339.05 GF Value. Its combined AI-and-data run rate already equals roughly 8.6% of annualized quarterly revenue, but Snowflake's breakout cannot prove Salesforce will capture the same budgets. The sector signal is flashing green. Renewals, consumption and margins must finish the job.